CD19 CAR-T cells (Beijing GoBroad Hospital)

CD19 CAR-T cells (Beijing GoBroad Hospital) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Beijing GoBroad Hospital for the treatment of refractory autoimmune diseases. The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically targets CD19, a surface antigen found on B cells. By targeting CD19, the therapy induces the depletion of pathogenic B cells and plasma cell precursors, which are central to the production of autoantibodies in various autoimmune conditions. It is currently being evaluated in a Phase 1/2 clinical trial for patients with systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic sclerosis, antiphospholipid syndrome, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.

Other names

CD19 CAR-T cellsCD-19 CAR-T cellsCD 19 CAR-T cells